Insider Buying: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Purchases $605,508.80 in Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler bought 116,444 shares of the business’s stock in a transaction that occurred on Thursday, November 18th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $605,508.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ AXDX opened at $5.49 on Thursday. Accelerate Diagnostics, Inc. has a 52 week low of $5.01 and a 52 week high of $15.60. The business has a 50-day simple moving average of $5.95 and a two-hundred day simple moving average of $6.74. The company has a market cap of $337.63 million, a P/E ratio of -4.39 and a beta of 1.80.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings results on Tuesday, November 9th. The medical research company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.20. During the same period in the previous year, the firm earned ($0.33) earnings per share. On average, equities research analysts predict that Accelerate Diagnostics, Inc. will post -1.46 EPS for the current fiscal year.

Separately, Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, October 20th.

Several institutional investors and hedge funds have recently bought and sold shares of AXDX. Marshall Wace LLP purchased a new stake in Accelerate Diagnostics in the first quarter worth $318,000. FMR LLC grew its stake in Accelerate Diagnostics by 16.1% in the first quarter. FMR LLC now owns 857,069 shares of the medical research company’s stock worth $18,016,000 after purchasing an additional 118,620 shares during the period. Ironwood Wealth Management LLC. grew its stake in Accelerate Diagnostics by 417.8% in the first quarter. Ironwood Wealth Management LLC. now owns 7,523 shares of the medical research company’s stock worth $63,000 after purchasing an additional 6,070 shares during the period. JPMorgan Chase & Co. grew its stake in Accelerate Diagnostics by 37.8% in the first quarter. JPMorgan Chase & Co. now owns 19,538 shares of the medical research company’s stock worth $162,000 after purchasing an additional 5,358 shares during the period. Finally, Nuveen Asset Management LLC grew its stake in Accelerate Diagnostics by 1.8% in the first quarter. Nuveen Asset Management LLC now owns 451,551 shares of the medical research company’s stock worth $3,757,000 after purchasing an additional 7,897 shares during the period. 67.27% of the stock is currently owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.

Recommended Story: What is the cash asset ratio?

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.